STOCK TITAN

R1 RCM Reports Third Quarter 2024 Results

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

R1 RCM reported its Q3 2024 financial results with revenue of $656.8 million, representing a 14.7% increase year-over-year. The company posted a GAAP net loss of $19.9 million, compared to net income of $1.3 million in Q3 2023. Adjusted EBITDA decreased to $148.2 million from $161.5 million in the same period last year. The quarter's performance was impacted by vendor and customer technology outages. Due to a previously announced proposed acquisition, R1 RCM is not providing financial guidance.

R1 RCM ha riportato i risultati finanziari del terzo trimestre 2024 con entrate pari a 656,8 milioni di dollari, che rappresentano un aumento del 14,7% rispetto all'anno precedente. L'azienda ha registrato una perdita netta GAAP di 19,9 milioni di dollari, rispetto a un utile netto di 1,3 milioni di dollari nel terzo trimestre 2023. EBITDA rettificato è sceso a 148,2 milioni di dollari rispetto ai 161,5 milioni di dollari dello stesso periodo dell'anno scorso. Le performance del trimestre sono state influenzate da interruzioni tecnologiche di fornitori e clienti. A causa di un'acquisizione proposta precedentemente annunciata, R1 RCM non fornisce previsioni finanziarie.

R1 RCM reportó sus resultados financieros del tercer trimestre de 2024 con ingresos de 656,8 millones de dólares, lo que representa un aumento del 14,7% en comparación con el año anterior. La empresa registró una pérdida neta GAAP de 19,9 millones de dólares, en comparación con una ganancia neta de 1,3 millones de dólares en el tercer trimestre de 2023. EBITDA ajustado disminuyó a 148,2 millones de dólares desde los 161,5 millones de dólares en el mismo período del año pasado. El rendimiento del trimestre se vio afectado por interrupciones tecnológicas de proveedores y clientes. Debido a una adquisición propuesta que fue anunciada anteriormente, R1 RCM no está proporcionando orientación financiera.

R1 RCM은 2024년 3분기 재무 결과를 보고했으며, 매출이 6억 5680만 달러에 달하여 전년 대비 14.7% 증가했습니다. 이 회사는 GAAP 기준에서 1990만 달러의 순손실을 기록했으며, 이는 2023년 3분기의 순이익 130만 달러와 비교됩니다. 조정된 EBITDA는 지난해 같은 기간의 1억 6150만 달러에서 1억 4820만 달러로 감소했습니다. 이번 분기 성과는 공급업체 및 고객의 기술 오류에 영향을 받았습니다. 이전에 발표된 제안된 인수로 인해 R1 RCM은 재무 예측을 제공하지 않습니다.

R1 RCM a publié ses résultats financiers pour le troisième trimestre 2024 avec un chiffre d'affaires de 656,8 millions de dollars, ce qui représente une augmentation de 14,7 % par rapport à l'année précédente. L'entreprise a enregistré une perte nette GAAP de 19,9 millions de dollars, contre un bénéfice net de 1,3 million de dollars au troisième trimestre 2023. EBITDA ajusté a diminué à 148,2 millions de dollars, contre 161,5 millions de dollars au cours de la même période de l'année dernière. Les performances du trimestre ont été impactées par des pannes technologiques chez les fournisseurs et les clients. En raison d'une acquisition proposée précédemment annoncée, R1 RCM ne fournit pas de prévisions financières.

R1 RCM hat seine finanziellen Ergebnisse für das dritte Quartal 2024 mit Umsätzen von 656,8 Millionen Dollar veröffentlicht, was einem Anstieg von 14,7 % im Vergleich zum Vorjahr entspricht. Das Unternehmen verzeichnete einen GAAP-Nettoverlust von 19,9 Millionen Dollar, im Vergleich zu einem Nettogewinn von 1,3 Millionen Dollar im dritten Quartal 2023. Bereinigtes EBITDA fiel von 161,5 Millionen Dollar im gleichen Zeitraum des Vorjahres auf 148,2 Millionen Dollar. Die Leistung des Quartals wurde durch technische Ausfälle von Anbietern und Kunden beeinträchtigt. Aufgrund einer zuvor angekündigten vorgeschlagenen Akquisition gibt R1 RCM keine Finanzprognosen heraus.

Positive
  • Revenue growth of 14.7% year-over-year to $656.8 million
  • Successful onboarding of new end-to-end partner
Negative
  • GAAP net loss of $19.9 million compared to prior year profit of $1.3 million
  • Adjusted EBITDA declined to $148.2 million from $161.5 million year-over-year
  • Operational disruptions from vendor and customer technology outages

Insights

The Q3 2024 results reveal a mixed financial picture for R1 RCM. While revenue grew by 14.7% year-over-year to $656.8 million, the company swung to a GAAP net loss of $19.9 million from a profit of $1.3 million in the previous year. The adjusted EBITDA declined to $148.2 million from $161.5 million.

The performance was significantly impacted by vendor and customer technology outages, affecting both revenue generation and cost structures. The company's ongoing acquisition status has led to the suspension of financial guidance, creating uncertainty around future performance metrics. The contrast between revenue growth and profitability decline suggests operational challenges in maintaining margins amid expansion efforts.

The reported technology outages affecting R1's operations highlight significant vulnerabilities in their service delivery model. As a technology-driven healthcare solutions provider, system reliability is important for maintaining customer satisfaction and operational efficiency. The impact on both revenue and costs indicates these weren't minor disruptions but rather substantial technical challenges that affected core business functions.

The successful onboarding of a new end-to-end partner despite these technical challenges demonstrates some resilience in their implementation capabilities, but the outages raise concerns about infrastructure robustness and disaster recovery protocols.

MURRAY, Utah, Nov. 05, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM) (“R1” or the “Company”), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced results for the three months ended September 30, 2024.

Third Quarter 2024 Results:

  • Revenue of $656.8 million, up $84.0 million or 14.7% compared to the same period last year.
  • GAAP net loss of $19.9 million, compared to net income of $1.3 million in the same period last year.
  • Adjusted EBITDA of $148.2 million, compared to adjusted EBITDA of $161.5 million in the same period last year.

The quarter reflects impacts to both revenue and costs as a result of recent vendor and customer outages.

“R1 continued to successfully execute the onboarding of our newest end-to-end partner while navigating previously disclosed industry and customer-specific technology outages,” stated Jennifer Williams, R1 CFO. “We are proud of the work our global associates are doing on behalf of our customers and remain committed to delivering positive outcomes for the provider industry.”

Guidance

Due to the previously announced proposed acquisition of R1, the Company is not providing financial guidance.

Non-GAAP Financial Measures

In order to provide a more comprehensive understanding of the information used by R1’s management team in financial and operational decision making, the Company supplements its GAAP consolidated financial statements with certain non-GAAP financial measures, including adjusted EBITDA, non-GAAP cost of services, non-GAAP selling, general and administrative expenses, and net debt. Adjusted EBITDA is defined as GAAP net income (loss) before net interest income/expense, income tax provision/benefit, depreciation and amortization expense, including the amortization of cloud computing arrangement implementation fees, share-based compensation expense, CoyCo 2, L.P. (“CoyCo 2”) share-based compensation expense, and certain other items, including costs incurred in connection with acquisition and integration initiatives, including costs related to the proposed Merger, exit activities, strategic and transformation initiatives to improve the Company’s business alignment and cost structure, review of strategic alternatives, and stockholder litigation. Non-GAAP cost of services is defined as GAAP cost of services less share-based compensation expense, CoyCo 2 share-based compensation expense, and depreciation and amortization expense attributed to cost of services. Non-GAAP selling, general and administrative expenses is defined as GAAP selling, general and administrative expenses less share-based compensation expense, CoyCo 2 share-based compensation expense, and depreciation and amortization expense attributed to selling, general and administrative expenses. Net debt is defined as debt less cash and cash equivalents, inclusive of restricted cash. Adjusted EBITDA guidance is reconciled to operating income guidance, the most closely comparable available GAAP measure.

Our board of directors and management team use adjusted EBITDA as (i) one of the primary methods for planning and forecasting overall expectations and for evaluating actual results against such expectations and (ii) a performance evaluation metric in determining achievement of certain executive incentive compensation programs, as well as for incentive compensation programs for employees. Non-GAAP cost of services and non-GAAP selling, general and administrative expenses are used to calculate adjusted EBITDA. Net debt is used as a supplemental measure of our liquidity.

Tables 4 through 7 present a reconciliation of GAAP financial measures to non-GAAP financial measures. Non-GAAP measures should be considered in addition to, but not as a substitute for, the information prepared in accordance with GAAP.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, included in this press release are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “designed,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “outlook,” “plan,” “predict,” “project,” “see,” “seek,” “target,” “would” and similar expressions or variations or negatives of these words are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such forward-looking statements include, among other things, statements about the Company’s current expectations relating to the merger of Project Raven Merger Sub, Inc. with and into the Company, with the Company continuing as the surviving corporation (the “Merger”) and the other transactions contemplated in the Merger Agreement, dated as of July 31, 2024, among the Company, Raven Acquisition Holdings, LLC and Project Raven Merger Sub, Inc.(collectively, the “Transaction”), the Company’s strategy, future operations, future financial position, projected costs, prospects, plans, challenges faced by health systems and their revenue cycle operations and the role of business therein, objectives of management, ability to successfully deliver on commitments to customers, impacts of recent cyberattacks, including the Ascension cyberattack and the Change Healthcare cyberattack, and a customer bankruptcy on the business, ability to deploy new business as planned, ability to successfully implement new technologies, ability to complete or integrate acquisitions as planned and to realize the expected benefits from acquisitions, including the acquisition of Acclara, the expected outcome or impact of pending or threatened litigation, and expected market growth. Such forward-looking statements are based on management’s current expectations about future events as of the date hereof and involve many risks and uncertainties that could cause the Company’s actual results to differ materially from those expressed or implied in its forward-looking statements. Subsequent events and developments, including actual results or changes in the Company’s assumptions, may cause the Company’s views to change. The Company does not undertake to update its forward-looking statements except to the extent required by applicable law. Readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements included herein are expressly qualified in their entirety by these cautionary statements. The Company’s actual results and outcomes could differ materially from those included in these forward-looking statements as a result of various factors, including, but not limited to, the completion of the Transaction on anticipated terms and timing or at all, including obtaining required stockholder approval, and the satisfaction of other conditions to the completion of the Transaction; the ability of affiliates of Raven Acquisition Holdings, LLC to obtain the necessary financing arrangements set forth in the commitment letters received in connection with the Transaction; the risk that disruptions from the Transaction, including the diversion of management’s attention from the Company’s ongoing business operations and the previously disclosed expected Chief Executive Officer succession in connection with the Transaction will harm the Company’s business, including current plans and operations; the Company’s ability to retain and hire key personnel in light of the Transaction; potential adverse reactions or changes to business relationships resulting from the announcement or completion of the Transaction; litigation relating to the Transaction instituted against the Company and the members of the Company’s Board of Directors arising out of the Merger, including the effects or any outcomes related thereto, which may delay or prevent the Merger; economic downturns and market conditions beyond the Company’s control, including high inflation; the quality of global financial markets; the Company’s ability to timely and successfully achieve the anticipated benefits and potential synergies of the acquisitions of Cloudmed and Acclara; the Company’s ability to retain existing customers or acquire new customers; the development of markets for the Company’s revenue cycle management offering; variability in the lead time of prospective customers; competition within the market; breaches or failures of the Company’s or their vendors’ information security measures or unauthorized access to a customer’s data; delayed or unsuccessful implementation of the Company’s technologies or services, or unexpected implementation costs; disruptions in or damages to the Company’s global business services centers, third-party operated data centers or other services provided by other third-parties; the volatility of the Company’s stock price; the Company’s substantial indebtedness; and the factors set forth under the heading “Risk Factors” in the Company’s most recent annual report on Form 10-K, and any other periodic reports that the Company may file with the U.S. Securities and Exchange Commission.

About R1 RCM

R1 is a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers. R1’s proven and scalable operating models seamlessly complement a healthcare organization’s infrastructure, quickly driving sustainable improvements to net patient revenue and cash flows while driving revenue yield, reducing operating costs, and enhancing the patient experience. To learn more, visit: r1rcm.com.

Contact:

R1 RCM Inc.

Investor Relations:

Evan Smith, CFA
516-743-5184
investorrelations@r1rcm.com

Media Relations:

Josh Blumenthal
media@r1rcm.com

Table 1
R1 RCM Inc.
Consolidated Balance Sheets
(In millions)
  (Unaudited)  
  September 30, December 31,
  2024 2023
Assets    
Current assets:    
Cash and cash equivalents $167.3  $173.6 
Accounts receivable, net of $27.7 million and $48.2 million allowance as of September 30, 2024 and December 31, 2023, respectively  317.6   243.3 
Accounts receivable - related party, net of $0.1 million allowance as of September 30, 2024 and December 31, 2023  38.4   26.1 
Current portion of contract assets, net  100.8   94.4 
Prepaid expenses and other current assets  144.8   95.9 
Total current assets  768.9   633.3 
Property, equipment and software, net  209.3   173.7 
Operating lease right-of-use assets  71.8   62.5 
Non-current portion of contract assets, net  43.3   37.7 
Non-current portion of deferred contract costs  34.3   30.4 
Intangible assets, net  1,508.8   1,310.7 
Goodwill  3,045.6   2,629.4 
Deferred tax assets  10.8   10.9 
Other assets  56.5   71.6 
Total assets $5,749.3  $4,960.2 
Liabilities     
Current liabilities:    
Accounts payable $34.4  $22.7 
Current portion of customer liabilities  55.0   39.8 
Current portion of customer liabilities - related party  5.3   5.2 
Accrued compensation and benefits  152.3   126.3 
Current portion of operating lease liabilities  22.7   19.3 
Current portion of long-term debt  72.8   67.0 
Accrued expenses and other current liabilities  87.1   65.9 
Total current liabilities  429.6   346.2 
Non-current portion of customer liabilities  1.9   2.7 
Non-current portion of customer liabilities - related party  10.4   11.8 
Non-current portion of operating lease liabilities  82.2   77.8 
Long-term debt  2,136.7   1,570.5 
Deferred tax liabilities  243.5   176.6 
Other non-current liabilities  33.9   23.2 
Total liabilities  2,938.2   2,208.8 
     
Stockholders’ equity:    
Common stock  4.5   4.5 
Additional paid-in capital  3,334.7   3,197.4 
Accumulated deficit  (199.3)  (136.7)
Accumulated other comprehensive loss  (11.3)  (5.9)
Treasury stock  (317.5)  (307.9)
Total stockholders’ equity  2,811.1   2,751.4 
Total liabilities and stockholders’ equity $5,749.3  $4,960.2 
         


Table 2
R1 RCM Inc.
Consolidated Statements of Operations (Unaudited)
(In millions, except share and per share data)
         
  Three Months Ended
September 30,
 Nine Months Ended
September 30,
  2024 2023 2024 2023
Net operating fees $413.0  $368.0 $1,169.1  $1,086.8
Incentive fees  22.4   30.1  59.7   84.5
Modular and other  221.4   174.7  659.8   507.8
Net services revenue  656.8   572.8  1,888.6   1,679.1
Operating expenses:        
Cost of services  545.5   447.5  1,549.4   1,328.1
Selling, general and administrative  62.3   54.7  184.9   164.3
Other expenses  33.2   29.4  101.4   87.9
Total operating expenses  641.0   531.6  1,835.7   1,580.3
Income from operations  15.8   41.2  52.9   98.8
Net interest expense  43.2   32.1  128.1   95.3
Income (loss) before income tax provision (benefit)  (27.4)  9.1  (75.2)  3.5
Income tax provision (benefit)  (7.5)  7.8  (12.6)  1.6
Net income (loss) $(19.9) $1.3 $(62.6) $1.9
         
Net income (loss) per common share:        
Basic $(0.05) $ $(0.15) $
Diluted $(0.05) $ $(0.15) $
Weighted average shares used in calculating net income (loss) per common share:        
Basic  422,101,172   419,008,998  421,289,787   418,299,910
Diluted  422,101,172   456,364,024  421,289,787   454,837,597
               


Table 3
R1 RCM Inc.
Consolidated Statements of Cash Flows (Unaudited)
(In millions)
     
  Nine Months Ended September 30,
  2024 2023
Operating activities    
Net income (loss) $(62.6) $1.9 
Adjustments to reconcile net income (loss) to net cash provided by operating activities:        
Depreciation and amortization  242.7   205.6 
Amortization of debt issuance costs  5.7   4.3 
Share-based compensation  46.8   48.9 
CoyCo 2 share-based compensation  12.7   5.4 
Loss on disposal and right-of-use asset write-downs  0.6   10.3 
Provision for credit losses  3.0   24.1 
Deferred income taxes  (13.9)  (1.5)
Non-cash lease expense  10.2   8.7 
Other  4.7   3.6 
Changes in operating assets and liabilities:    
Accounts receivable and related party accounts receivable  (41.9)  (36.7)
Contract assets  (11.8)  (10.0)
Prepaid expenses and other assets  (44.6)  (22.0)
Accounts payable  5.8   (15.0)
Accrued compensation and benefits  4.0   12.0 
Lease liabilities  (16.3)  (13.4)
Other liabilities  5.6   12.9 
Customer liabilities and customer liabilities - related party  21.9   (17.8)
Net cash provided by operating activities  172.6   221.3 
Investing activities    
Purchases of property, equipment, and software  (83.6)  (81.1)
Acquisition of Acclara, net of cash acquired  (662.0)   
Other  (7.1)  5.5 
Net cash used in investing activities  (752.7)  (75.6)
Financing activities    
Issuance of senior secured debt, net of discount and issuance costs  561.5    
Borrowings on revolver  155.0   30.0 
Repayment of senior secured debt  (54.6)  (37.1)
Repayments on revolver  (95.0)  (70.0)
Refund of inducement dividend  16.4    
Payment of equity issuance costs  (0.4)   
Exercise of vested stock options  1.4   1.3 
Shares withheld for taxes  (9.7)  (20.0)
Other  (0.3)  5.3 
Net cash provided by (used in) financing activities  574.3   (90.5)
Effect of exchange rate changes in cash, cash equivalents and restricted cash  (0.5)  (0.4)
Net (decrease) increase in cash, cash equivalents and restricted cash  (6.3)  54.8 
Cash, cash equivalents and restricted cash, at beginning of period  173.6   110.1 
Cash, cash equivalents and restricted cash, at end of period $167.3  $164.9 
         


Table 4
R1 RCM Inc.
Reconciliation of GAAP Net Income (Loss) to Non-GAAP Adjusted EBITDA (Unaudited)
(In millions, except percentages)
                 
  Three Months Ended
September 30,
 2024 vs. 2023
Change
 Nine Months Ended
September 30,
 2024 vs. 2023
Change
  2024 2023 Amount % 2024 2023 Amount %
Net income (loss) $(19.9) $1.3 $(21.2) n.m. $(62.6) $1.9 $(64.5) n.m.
Net interest expense  43.2   32.1  11.1  35%  128.1   95.3  32.8  34%
Income tax provision (benefit)  (7.5)  7.8  (15.3) (196)%  (12.6)  1.6  (14.2) (888)%
Depreciation and amortization expense  83.2   70.8  12.4  18%  242.7   205.6  37.1  18%
Share-based compensation expense  6.8   18.4  (11.6) (63)%  46.8   48.9  (2.1) (4)%
CoyCo 2 share-based compensation expense  9.2   1.7  7.5  441%  12.7   5.4  7.3  135%
Other expenses (1)  33.2   29.4  3.8  13%  101.4   87.9  13.5  15%
Adjusted EBITDA (non-GAAP) $148.2  $161.5 $(13.3) (8)% $456.5  $446.6 $9.9  2%
                            

(1) For details, see Note 9 to the Condensed Consolidated Financial Statements included in the Company’s Quarterly Report on Form 10-Q.

Table 5
R1 RCM Inc.
Reconciliation of GAAP Cost of Services to Non-GAAP Cost of Services (Unaudited)
(In millions)
         
  Three Months Ended
September 30,
 Nine Months Ended
September 30,
  2024 2023 2024 2023
Cost of services $545.5 $447.5 $1,549.4 $1,328.1
Less:        
Share-based compensation expense  5.1  11.9  28.2  30.7
CoyCo 2 share-based compensation expense  1.8  0.5  2.6  1.4
Depreciation and amortization expense  82.0  70.4  239.9  204.6
Non-GAAP cost of services $456.6 $364.7 $1,278.7 $1,091.4
             


Table 6
R1 RCM Inc.
Reconciliation of GAAP Selling, General and Administrative to Non-GAAP Selling, General and Administrative (Unaudited)
(In millions)
         
  Three Months Ended
September 30,
 Nine Months Ended
September 30,
  2024 2023 2024 2023
Selling, general and administrative $62.3 $54.7 $184.9 $164.3
Less:        
Share-based compensation expense  1.7  6.5  18.6  18.2
CoyCo 2 share-based compensation expense  7.4  1.2  10.1  4.0
Depreciation and amortization expense  1.2  0.4  2.8  1.0
Non-GAAP selling, general and administrative $52.0 $46.6 $153.4 $141.1
             


Table 7
R1 RCM Inc.
Reconciliation of Total Debt to Net Debt (Unaudited)
(In millions)
     
  September 30, December 31,
  2024 2023
Senior Revolver $60.0 $
Term A Loans  1,116.0  1,162.5
Term B Loans  1,060.6  493.8
Total debt  2,236.6  1,656.3
     
Less:    
Cash and cash equivalents  167.3  173.6
Net Debt $2,069.3 $1,482.7
       

FAQ

What was R1 RCM's (RCM) revenue in Q3 2024?

R1 RCM reported revenue of $656.8 million in Q3 2024, an increase of 14.7% compared to the same period last year.

How much was R1 RCM's (RCM) net loss in Q3 2024?

R1 RCM reported a GAAP net loss of $19.9 million in Q3 2024, compared to a net income of $1.3 million in Q3 2023.

What was R1 RCM's (RCM) Adjusted EBITDA for Q3 2024?

R1 RCM's Adjusted EBITDA was $148.2 million in Q3 2024, down from $161.5 million in the same period last year.

Why isn't R1 RCM (RCM) providing financial guidance for 2024?

R1 RCM is not providing financial guidance due to a previously announced proposed acquisition of the company.

R1 RCM Inc.

NASDAQ:RCM

RCM Rankings

RCM Latest News

RCM Stock Data

6.04B
198.59M
1.04%
86.86%
2.56%
Health Information Services
Services-management Services
Link
United States of America
MURRAY